San Carlos, CA February 21, 2012 - Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that Lowell E. Sears joined its Board of Directors effective today.
Mr. Sears is currently Chairman and CEO of Sears Capital Management, a venture investment and portfolio management firm specializing in life sciences. He has been an active life science venture investor since 1994, helping to found and fund over forty companies. From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., where he held positions of Chief Financial Officer as well as Senior Vice President responsible for the Asia Pacific Region.
"Lowell has had a distinguished biotechnology career and is highly regarded in the industry. I am delighted to welcome him to our board," said Ram Mandalam, President and CEO of Cellerant. "His broad experience in strategic planning, corporate financing and overall management and operational skills will be very useful to us as we continue to develop our programs and build shareholder value."
"On behalf of all of our directors I am delighted to welcome Lowell to our board," said Richard Rathmann, Cellerant's Chairman of the Board. "Throughout his career at Amgen and other biotechnology companies, Lowell has been directly involved in building and developing successful companies as they advance to the next stage."
Prior to joining to Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company (ARCO) from 1976 until 1986, including a period as Chief Financial Officer for its Ventures Division. Mr. Sears has served on twenty boards of directors, including roles as board chairman and audit committee chair. He currently serves on the board of SymBio Pharmaceuticals, KK, Ltd. (JASDAQ: 4582).
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome. For more information, visit: http://www.cellerant.com.
For more information on Cellerant, please contact:
Cellerant Therapeutics, Inc.
Executive Director, Corporate Development